ONE MAIN STREET, CAMBRIDGE, MA
To Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Financial Results, Press Release
Provides Corporate Update and Highlights Anticipated 2026 Milestones
Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
Cullinan Therapeutics Terminates Exclusive Patent License Agreement with MIT
Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Correspondence
Submission Upload